text
"['\n3. 타법인출자 현황(상세)\n☞ 본문 위치로 이동\n(기준일 :\xa0\n2023년 06월 30일\n)\n(단위 : 천원, 주, %)\n법인명\n상장여부\n최초취득일자\n출자목적\n최초취득금액\n기초잔액\n증가(감소)\n기말잔액\n최근사업연도재무현황\n수량\n지분율\n장부가액\n취득(처분)\n평가손익\n수량\n지분율\n장부가액\n총자산\n당기순손익\n수량\n금액\n한올바이오파마(주)\n상장\n2015.07.30\n경영참여\n116,111,366\n16,115,745\n31.79\n116,111,366\n-\n-\n-\n16,115,745\n31.79\n116,111,366\n207,502,159\n546,481\n힐리언스\n비상장\n2006.03.30\n경영참여\n27,310,924\n2,853,300\n78.73\n15,620,220\n-\n-\n-\n2,853,300\n78.73\n15,620,220\n30,378,730\n1,117,367\nDaewoong Pharma PHILIPPINES, INC.\n비상장\n2007.04.12\n경영참여\n260,539\n-\n100\n260,539\n-\n-\n-\n-\n100\n260,539\n2,837,365\n33,434\nDaewoong Pharmaceutical(Thailand)Co.,Ltd\xa0\n비상장\n2007.08.22\n경영참여\n205,389\n-\n100\n205,389\n-\n-\n-\n-\n100\n205,389\n1,622,811\n46,472\nPT. DAEWOONG PHARMACEUTICAL COMPANY INDONESIA\xa0\n비상장\n2006.04.01\n경영참여\n7,812,111\n30,825,649\n100\n27,865,665\n-\n-\n-\n30,825,649\n100\n27,865,665\n25,450,878\n1,887,541\nDAEWOONG PHARMACEUTICAL HONGKONG\xa0\n비상장\n2013.08.05\n경영참여\n17,660,725\n269,255,424\n89.83\n37,184,429\n-\n-\n-\n269,255,424\n89.83\n37,184,429\n48,587,232\n-18,552\n북경대웅위업의약과기유한공사\n비상장\n2007.08.16\n경영참여\n9,152,033\n-\n100\n5,827,683\n-\n-\n-\n-\n100\n5,827,683\n2,950,404\n490,166\n(주)바이오시네틱스\n비상장\n2013.05.19\n공동연구추진\n2,000,000\n645,000\n17.96\n-\n-\n-\n-\n645,000\n17.96\n-\n671,610\n-326,536\n(주)이피피미디어\xa0\n비상장\n2008.01.25\n사업목적\n1,000,000\n100,000\n20\n-\n-\n-\n-\n100,000\n20\n-\n6,297,288\n-66,020\n(주)엠디웰아이엔씨\n비상장\n2007.07.18\n경영참여\n500,000\n100,000\n50\n500,000\n-\n-\n-\n100,000\n50\n500,000\n12,335,830\n915,786\nDaewoong America, Inc.\n비상장\n2009.12.30\n경영참여\n825,005\n-\n100\n83,287\n-\n-\n-\n-\n100\n83,287\n45,976\n-11,001\nDaewoong Pharmaceutical India Pvt.,Ltd\xa0\n비상장\n2013.02.01\n경영참여\n550,733\n-\n100\n550,733\n-\n-\n-\n-\n100\n550,733\n2,330,837\n-65,732\nDAEWOONG PHARMACEUTICAL JAPAN CO.,LTD\n비상장\n2017.03.08\n경영참여\n555,621\n1,100\n100\n555,621\n-\n-\n-\n1,100\n100\n555,621\n2,910,514\n683,666\n건강한삶기술창업벤처PEF\xa0\n비상장\n2018.03.19\n사업목적\n2,500,000\n2,500,000,000\n49.5\n2,500,000\n-\n-\n-\n2,500,000,000\n49.5\n2,500,000\n4,495,253\n-69,601\n㈜다나아데이터\n비상장\n2018.11.23\n경영참여\n5,100,000\n102,000\n51\n5,100,000\n-\n-\n-\n102,000\n51\n5,100,000\n10,274,785\n66,499\nImmplacate, Inc.\n비상장\n2019.03.08\n공동연구추진\n1,125,970\n1,428,571\n20\n228,856\n-\n-\n-\n1,428,571\n20\n228,856\n149,731\n-260,766\n(주)아피셀테라퓨틱스\n비상장\n2020.01.23\n경영참여\n1,960,780\n3,796,216\n62.14\n10,815,050\n-\n-\n-\n3,796,216\n62.14\n10,815,050\n27,351,360\n-12,215,830\n(주)아이엔테라퓨틱스\n비상장\n2020.05.27\n경영참여\n3,118,330\n19,115,085\n93.91\n8,118,330\n-\n-\n-\n19,115,085\n93.91\n8,118,330\n27,764,577\n-2,108,597\nDaewoong Innovation Holdings\n비상장\n2021.07.14\n경영참여\n-\n-\n100\n2,355,900\n-\n-\n-\n-\n100\n2,355,900\n2,519,541\n-18,850\nEvolus.INC(해외상장)(주2)\n상장\n2021.03.23\n사업목적\n-\n3,136,869\n5.75\n29,854,908\n-\n-\n83,544\n3,136,869\n5.75\n29,938,452\n177,983\n-74,412\n진켐\n비상장\n2000.04.01\n공동연구추진\n559,660\n41,932\n0.46\n177,624\n-\n-\n-\n41,932\n0.46\n177,624\n40,537,161\n-5,761,322\n바이오넷\n비상장\n2001.12.22\n사업목적\n1,207,646\n324,480\n1.95\n227,136\n-\n-\n-\n324,480\n1.95\n227,136\n19,455,700\n1,129,693\n큐어컴퍼니\n비상장\n2009.07.01\n공동연구추진\n217,377\n31,110\n1.24\n24,574\n-\n-\n-\n31,110\n1.24\n24,574\n7,859,739\n-3,161,128\n3D Matrix (해외상장)(주1)\n상장\n2010.09.01\n사업목적\n1,362,230\n320,000\n1.49\n939,455\n-\n-\n-440,257\n320,000\n1.49\n499,198\n7,132,308\n-3,240,855\n카이페리온\n비상장\n2019.10.16\n사업목적\n1,000,020\n28,572\n2.63\n1,000,020\n-\n-\n-\n28,572\n2.63\n1,000,020\n5,249,432\n-1,753,158\nJTBC\n비상장\n2011.04.01\n사업목적\n3,000,000\n600,000\n0.52\n419,400\n-\n-\n-\n600,000\n0.52\n419,400\n382,200,727\n14,600,000\n향남제약공단\n비상장\n2005.11.10\n일반참여\n217,879\n-\n-\n217,879\n-\n-\n-\n-\n-\n217,879\n6,355,711\n2,208\n자일자동차판매\n비상장\n2011.12.01\n일반참여\n827,695\n93,286\n0.45\n115,208\n-\n-\n-\n93,286\n0.45\n115,208\n306,907,322\n-583,462\n대우산업개발\n비상장\n2012.06.05\n일반참여\n592,014\n33,296\n0.43\n401,150\n-\n-\n-\n33,296\n0.43\n401,150\n284,886,115\n-31,346,622\n인벤티지랩\n상장\n2020.04.28\n기술성투자\n999,995\n83,326\n1.17\n814,928\n-\n-\n-71,660\n83,326\n1.17\n743,268\n34,861,902\n-10,595,328\n(주)입셀\n비상장\n2020.09.09\n기술성투자\n2,000,002\n9,091\n9.09\n2,000,002\n7,053\n2,999,852\n-\n16,144\n9.09\n4,999,854\n18,358,432\n-7,518,809\n데일리 임파워링 바이오 헬스케어 펀드4호\n비상장\n2020.09.23\n사업목적\n1,000,000\n1,000\n7\n863,481\n-\n-\n-\n1,000\n7\n863,481\n11,017,114\n-1,782,894\n유안타 퀀텀점프 3호 투자조합\n비상장\n2021.09.10\n사업목적\n-\n1,000\n14.29\n1,000,000\n-\n-\n-\n1,000\n14.29\n1,000,000\n6,859,116\n-144,260\n티온랩테라퓨틱스\n비상장\n2021.07.21\n사업목적\n-\n97,109\n14.78\n738,999\n21,903\n500,001\n-\n119,012\n14.78\n1,239,000\n2,068,847\n-1,135,393\n서울의료정보연구소\n비상장\n2020.12.11\n사업목적\n200,063\n1,067\n6.08\n200,063\n-\n-\n-\n1,067\n6.08\n200,063\n945,474\n406,305\nNurron Pharmaceuticals INC.(주2)\n비상장\n2021.09.10\n공동연구추진\n-\n58,343\n2.37\n570,549\n-\n-\n-\n58,343\n2.37\n570,549\n1,647,199\n-1,913,689\nNeurogastrx(주3)\n비상장\n2021.06.18\n사업목적\n-\n4,782,095\n5\n3,968,422\n-\n-\n-\n4,782,095\n5\n3,968,422\n35,216\n-35,462\n온코크로스\n비상장\n2021.04.01\n공동연구추진\n-\n79,284\n0.9\n1,000,036\n-\n-\n-\n79,284\n0.9\n1,000,036\n8,459,388\n-9,083,105\n넥스아이\n비상장\n2021.12.08\n공동연구추진\n-\n11,705\n4.35\n999,958\n-\n-\n-\n11,705\n4.35\n999,958\n22,714,627\n-5,720,725\n씨어스테크놀로지\n비상장\n2021.12.22\n사업목적\n-\n8,284\n3.16\n5,000,057\n-\n-\n-\n8,284\n3.16\n5,000,057\n21,292,890\n-7,988,275\n미래에셋-현대중공업 신성장투자조합1호\n비상장\n2021.11.01\n사업목적\n-\n400\n5.97\n400,000\n-\n-\n-\n400\n5.97\n400,000\n6,139,406\n-621,026\n에버그린투자파트너스4호펀드\n비상장\n2021.11.17\n사업목적\n-\n600\n2.32\n600,000\n-\n-\n-\n600\n2.32\n600,000\n25,008,718\n-777,082\n브이원바이오\n비상장\n2021.11.30\n사업목적\n-\n21,667\n8.86\n390,006\n-\n-\n-\n21,667\n8.86\n390,006\n474,826\n-610,689\n엑소스템텍\n비상장\n2021.12.30\n공동연구추진\n-\n38,865\n1.4\n999,996\n-\n-\n-\n38,865\n1.4\n999,996\n5,790,823\n-4,967,153\n베어리버(주3)\n비상장\n2022.03.31\n일반참여\n-\n59,520\n0.62\n297,600\n-\n-\n-\n59,520\n0.62\n297,600\n121,507,542\n5,206,684\n핀테라퓨틱스\n비상장\n2022.02.17\n공동연구추진\n-\n6,329\n1.25\n999,982\n-\n-\n-\n6,329\n1.25\n999,982\n9,255,682\n-13,229,312\n디시젠\n비상장\n2022.04.22\n사업목적\n-\n256\n1.59\n1,001,351\n-\n-\n-\n256\n1.59\n1,001,351\n9,660,172\n-3,205,279\n시너지에이아이\n비상장\n2022.04.29\n공동연구추진\n-\n7,000\n2.94\n499,996\n-\n-\n-\n7,000\n2.94\n499,996\n1,494,013\n-643,746\n메디아이오티\n비상장\n2022.05.13\n공동연구추진\n-\n629\n3.99\n199,709\n-\n-\n-\n629\n3.99\n199,709\n1,155,940\n-728,216\n켈스\n상장\n2022.10.05\n사업목적\n-\n92,592\n2.24\n999,993\n-\n-\n-\n92,592\n2.24\n999,993\n17,093,543\n-80,836\n차세대 지역 뉴딜&바이오투자조합\n비상장\n2022.10.28\n사업목적\n-\n600\n10\n600,000\n-\n-\n-\n600\n10\n600,000\n6,005,254\n-8\n셀타스퀘어\n비상장\n2022.11.14\n공동연구추진\n-\n20,000\n4.76\n400,000\n-\n-\n-\n20,000\n4.76\n400,000\n1,206,173\n-416,600\n에피바이오텍\n비상장\n2022.12.22\n공동연구추진\n-\n78,947\n2.62\n1,499,993\n-\n-\n-\n78,947\n2.62\n1,499,993\n9,524,102\n4,830,540\n이모티브\n비상장\n2022.12.26\n공동연구추진\n-\n685\n1.16\n159,810\n-\n-\n-\n685\n1.16\n159,810\n1,847,211\n-3,635\n휴먼스케이프\n비상장\n2022.10.21\n사업목적\n-\n2,799\n1.97\n1,999,986\n-\n-\n-\n2,799\n1.97\n1,999,986\n17,538,459\n34,468,398\n셀라톡스바이오파마\n비상장\n2022.12.28\n경영참여\n-\n990\n99\n802,824\n7,227\n6,278,489\n-\n8,217\n99.88\n7,081,313\n209,393\n-34\n바이옴에이츠\n비상장\n2023.03.22\n사업목적\n-\n-\n-\n-\n901\n300,033\n-\n901\n3.34\n300,033\n87,596\n-25,631\nAlloplex(주2)\n비상장\n2023.01.27\n사업목적\n-\n-\n-\n-\n9,794\n827,338\n-\n9,794\n0.27\n827,338\n3,481,511\n-1,574,452\n나위\n비상장\n2023.05.31\n사업목적\n-\n-\n-\n-\n20,000\n10,000\n-\n20,000\n10\n10,000\n-\n-\nVITALLI BIO, INC\n비상장\n2023.05.30\n사업목적\n-\n-\n-\n-\n2,098,132\n5,356,406\n-\n2,098,132\n16.67\n5,356,406\n-\n-\n합 계\n-\n-\n296,268,163\n2,165,010\n16,272,119\n-428,373\n-\n-\n312,111,909\n-\n-\n※ 상기 최근사업연도 재무현황은 22년 기말 재무제표 기준입니다.\n※ (주1) 3D Matrix는 4월 결산법인으로 2023년 4월말 기준 재무제표이며 재무현황 표기 단위는 1,000엔입니다.\n※ (주2) Evolus,INC., Nurron Pharmaceuticals INC., Neurogastrx, Alloplex 재무현황 표기 단위는 1,000달러입니다.\xa0\n※ (주3) 베어리버의 회생계획인가에 따라 취득한 주식입니다.[출자목적 세부 내용]\n법인명\n출자목적\n세부 목적\n큐어컴퍼니\n공동연구 추진\n폐암치료제 공동 R&D\nNurron\n공동연구 추진\n파킨슨 치료제 개발 업체 투자\n넥스아이\n공동연구 추진\n파이프라인 공동연구 개발\nImmplacate, Inc.\n공동연구 추진\n줄기세포치료제 공동연구/개발\n바이오시네틱스\n공동연구 추진\n나노기술 활용 신약개발\n온코크로스\n공동연구 추진\n공동연구 및 양사 협력관계 강화\n엑소스템텍\n공동연구 추진\nDW-MSC 엑소좀 파이프라인 확장/MOU 체결\n진켐\n공동연구 추진\nAnti-Sense 항암제 등 공동 R&D\n인벤티지랩\n기술성 투자\n장기지속형 주사제 파이프라인 발굴\n입셀\n기술성 투자\n유망 파이프라인 선확보\n브이원바이오\n사업목적\n마이크로바이옴 연구협력\n티온랩테라퓨틱스\n사업목적\n서방형 데포치료제 연구협력\nNeurogastrx\n사업목적\n펙수프라잔 미국 L/O 대금 일부에 대한 지분 취득\n씨어스테크놀로지\n사업목적\n패치형 심전도기/병상모니터링 관련 사업협업\nEvolus.INC(해외상장)\n사업목적\n파트너 재무구조 개선 및 파트너십 강화\nJTBC\n사업목적\n우호적인 종편채널 확보\n카이페리온\n사업목적\n신사업 O/C 강화\n서울의료정보연구소\n사업목적\n보건의료데이터 사업분야 전략적 협업\n바이오넷\n사업목적\n내시경 등 의료기기 사업 투자\n자일자동차판매\n일반참여\n투자수익 창출\n대우산업개발\n일반참여\n투자수익 창출\n3D Matrix (해외상장)\n사업목적\n흡수성 국소지혈제 국내 판권 확보\n에버그린투자파트너스4호펀드\n사업목적\n연구개발 스타트업 발굴\n미래에셋-현대중공업 신성장투자조합1호\n사업목적\n중장기 미래 파이프라인 동력 및 네트워크 확보\n데일리 임파워링 바이오 헬스케어 펀드4호\n사업목적\n바이오 기업 발굴 등 신사업 O/C 강화\n유안타 퀀텀점프 3호 투자조합\n사업목적\n목적펀드 내 투자회사와의 글로벌 사업 진출 협력\n건강한삶기술창업벤처PEF\xa0\n사업목적\n펀드참여\n메디아이오티\n공동연구추진\n이노베어 공모전 당선 회사로 협력모델 확보\n시너지 A.I.\n공동연구추진\n모비케어 차세대 제품개발 및 마케팅 파트너\nDC Gen\n사업목적\n온코프리(유방암 진단 키트) 글로벌 사업협력\n핀테라퓨틱스\n공동연구추진\n단백질분해(TPD) 신약개발 역량확보\n[장부가액 감액 사유]\n(단위: 천원)\n법인명\n감액금액\n감액 사유\n3D Matrix\n(440,257)\n공정가치 평가에 따른 감소\n인벤티지랩\n(71,660)\n']"
